Business Standard

Bajaj Healthcare locked in 10% upper circuit; hits record high on HCQ boost

The stock has rallied 28 per cent in the past four days after getting Gujarat Food and Drug Administration's (FDA) nod to manufacture hydhroxychloroquine sulphate.

drug, medicine, drugs, pharma, pharmaceutical
Premium

In the wake of Covid-19 pandemic, there has been a sudden interest the anti-malarial and anti-inflammatory drug.

SI Reporter Mumbai
Shares of Bajaj Healthcare were locked in the 10 per cent upper circuit, to hit an all-time high of Rs 304, on the BSE on Wednesday. The stock has rallied 28 per cent in the past four days after getting Gujarat Food and Drug Administration's (FDA) nod to manufacture hydhroxychloroquine sulphate.

Besides, the stock has rallied 40 per cent in the past one month, as against a 4.8 per cent rise in the S&P BSE Sensex during the period. The trading volumes on the counter more-than-doubled with 18,000 shares changing hands on the BSE till 02:49 pm. 

“The company

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in